Study of anemia management in dialysis patients
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study is testing a new way to manage anemia (low red blood cells) in people on long-term dialysis. It aims to improve how doctors treat this common issue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been on dialysis at least twice a week for 3 months or more
- You do not plan to get a kidney transplant or stop dialysis in the next 6 months
- You do not have bone marrow or inherited blood diseases
- You have no active stomach or intestinal bleeding and no recent serious infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This study looks at how common anemia is in people with chronic kidney disease in China. It may help doctors better understand and manage anemia for patients with kidney problems.
This trial tests an oral medication (AND017) for anemia caused by chronic kidney disease. It aims to improve red blood cell levels without needing dialysis or current anemia treatments.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This trial tests whether a new blood test (reticulocyte hemoglobin) is better than the usual iron test (transferrin saturation) for guiding when to give iron to people on dialysis. If you have anemia (low red blood cells) from kidney disease, this study may help doctors find the best way to treat your iron levels.
This study looks at how well erythropoietin (a drug that helps your body make red blood cells) works for people with end-stage kidney disease who are on regular hemodialysis. It also checks if metabolic syndrome (a group of conditions like high blood sugar, high blood pressure, and extra belly fat) affects how well this drug works.
Hear when a new Anemia of Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.